ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we report that the irreversible pan-FGFR inhibitor TAS-120 demonstrated efficacy in 4 patients with FGFR2 fusion–positive ICC who developed resistance to BGJ398 or Debio 1347. Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio 1347. Functional assessment and modeling the clonal outgrowth of individual resistance mutations from polyclonal cell pools mirrored the resistance profiles observed clinically for each inhibitor. Our findings suggest that strategic sequencing of FGFR inhibitors, guided by serial biopsy and ctDNA analysis, may prolong the duration of benefit from FGFR inhibition in patients with FGFR2 fusion–positive ICC. SIGNIFICANCE: ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2-altered ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models.

TAS-120 overcomes resistance to atp-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma

Siravegna G.;Bardelli A.;
2019-01-01

Abstract

ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we report that the irreversible pan-FGFR inhibitor TAS-120 demonstrated efficacy in 4 patients with FGFR2 fusion–positive ICC who developed resistance to BGJ398 or Debio 1347. Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio 1347. Functional assessment and modeling the clonal outgrowth of individual resistance mutations from polyclonal cell pools mirrored the resistance profiles observed clinically for each inhibitor. Our findings suggest that strategic sequencing of FGFR inhibitors, guided by serial biopsy and ctDNA analysis, may prolong the duration of benefit from FGFR inhibition in patients with FGFR2 fusion–positive ICC. SIGNIFICANCE: ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2-altered ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models.
2019
9
8
1064
1079
http://cancerdiscovery.aacrjournals.org/content/candisc/9/8/1064.full-text.pdf
Goyal L.; Shi L.; Liu L.Y.; de la Cruz F.F.; Lennerz J.K.; Raghavan S.; Leschiner I.; Elagina L.; Siravegna G.; Ng R.W.S.; Vu P.; Patra K.C.; Saha S.K.; Uppot R.N.; Arellano R.; Reyes S.; Sagara T.; Otsuki S.; Nadres B.; Shahzade H.A.; Dey-Guha I.; Fetter I.J.; Baiev I.; Van Seventer E.E.; Murphy J.E.; Ferrone C.R.; Tanabe K.K.; Deshpande V.; Harding J.J.; Yaeger R.; Kelley R.K.; Bardelli A.; Iafrate A.J.; Hahn W.C.; Benes C.H.; Ting D.T.; Hirai H.; Getz G.; Juric D.; Zhu A.X.; Corcoran R.B.; Bardeesy N.
File in questo prodotto:
File Dimensione Formato  
2019-TAS-120_postprint.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 19.3 MB
Formato Adobe PDF
19.3 MB Adobe PDF Visualizza/Apri
tas.full.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 6.22 MB
Formato Adobe PDF
6.22 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1728686
Citazioni
  • ???jsp.display-item.citation.pmc??? 99
  • Scopus 249
  • ???jsp.display-item.citation.isi??? 237
social impact